EGF mutant receptor vIII as a molecular target in cancer therapy

Endocrine-Related Cancer

Volumn 8, Issue 2, 2001, Pages 83-96

  Kuan, C T ^a   Wikstrand, C J ^a   Bigner, D D ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; IMMUNOTOXIN; MONOCLONAL ANTIBODY; MUTANT PROTEIN;

CANCER THERAPY; CONFERENCE PAPER; GENE AMPLIFICATION; GENE MUTATION; HUMAN; IMMUNOTHERAPY; MOLECULAR DYNAMICS; PROTEIN EXPRESSION;

ANIMALS; ANTIBODIES, MONOCLONAL; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; IMMUNOTHERAPY; IMMUNOTOXINS; MUTATION; NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 0034947649     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.0.0080083     Document Type: Conference Paper

References (84)

1. Expression of the epidermal growth factor receptor in astrocytic tumours is specifically associated with glioblastoma multiforme
2. Constitutive activation of c-Jun N-terminal kinase by a mutant epidermal growth factor receptor
3. Regional treatment of EGFRvIII-expressing neoplastic meningitis with a single chain immunotoxin MR1
4. In vitro generation of dendritic cells from the peripheral blood of patients with malignant gliomas for antigen specific immunotherapy
5. A genetically modified allogeneic cellular vaccine generates MHC class-restricted cytotoxic responses against tumor-associated antigens and protects against CNS tumor challenge
6. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors
7. Biology of disease: Oncogenes and anti-oncogenes in human central nervous system tumors
8. Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene
9. Immunotoxins with increased activity against epidermal growth factor receptor vIII-expressing cells produced by antibody phage display
10. Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts
11. Mechanisms of altered growth control. Cytogenetics, oncogenes and suppressor genes
12. Stimulation of lymphocytotoxic clones by anti-idiotypic antibodies: Basis for development of idiotypic vaccines
13. Some thoughts on the future of idiotypic vaccines
14. A complete description of the EGF-receptor exon structure: Implication in oncogenic activation and domain evolution
15. Epidermal growth factor
16. EGF receptor amplification and expression in human brain tumours
17. Receptor dimerization is not a factor in the signaling activity of a transforming variant epidermal growth factor receptor (EGFRvIII)
18. Oncogenic epidermal growth factor receptor mutants with tandem duplication: Gene structure and effects on receptor function
19. Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells
20. Genes for epidermal growth factor receptor, transforming growth factor α, and epidermal growth factor and their expression in human gliomas in vivo
21. Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails
22. Normoxic and hypoxic regulation of vascular endothelial growth factor (VEGF) by astrocytoma cells is mediated by Ras
23. Deletion and tandem duplication of exons 2-7 in the epidermal growth factor receptor gene of a human malignant glioma
24. Glycosylation-induced conformational modification positively regulates receptor-receptor association: A study with an aberrant epidermal growth factor receptor (EGFRvIII/DEGFR) expressed in cancer cells
25. Active specific T-cell-based immunotherapy for cancer: Nucleic acids, peptides, whole native proteins, recombinant viruses, with dendritic cell adjuvants or whole tumor cell-based vaccines. Principles and future prospects
26. Diphtheria toxin fusion proteins
27. Radioiodination via D-amino acid peptide enhances cellular retention and tumor xenograft targeting of an internalizing anti-epidermal growth factor receptor variant III monoclonal antibody
28. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas
29. Expression of mutated epidermal growth factor receptor by non-small cell lung carcinomas
30. Phase I clinical study of the recombinant oncotoxin TP40 in superficial bladder cancer
31. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model
32. Cancer statistics
33. Type I growth factor receptors: Current status and future work
34. Tyrphostin AG 1478 preferentially inhibits human glioma cells expressing truncated rather than wild-type epidermal growth factor receptors
35. Specific targeting of a mutant, activated EGF receptor found in glioblastoma using a monoclonal antibody
36. The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling
37. Amplification and expression of the epidermal growth factor receptor gene in human glioma xenografts
38. Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma
39. Deletion-mutant epidermal growth factor receptor in human gliomas: Effects of type II mutation on receptor function
40. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies
41. 125I-labeled anti-epidermal growth factor receptor-vIII single chain Fv exhibits specific and high-level targeting of glioma xenografts
42. Increased binding affinity enhances targeting of glioma xenografts by EGFRvIII-specific scFv
43. Expression of epidermal growth factor receptors in human brain tumors
44. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin
45. Immunotoxins that target an oncogenic mutant epidermal growth factor receptor expressed in human tumors
46. Recombinant immunotoxins specific for a mutant epidermal growth factor receptor: Targeting with a single chain antibody variable domain isolated by phage display
47. Glioma-associated antigen expression in oligodendroglial neoplasms
48. Epidermal growth factor reduces HER-2 protein level in human ovarian carcinoma cells
49. Expression of oncogenic epidermal growth factor receptor family kinases induces paclitaxel resistance and alters beta-tubulin isotype expression
50. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors
51. Transformation and altered signal transduction by a naturally occurring mutant EGF receptor
52. A naturally occurring mutant human epidermal growth factor receptor as a target for peptide vaccine immmunotherapy of tumors
53. Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor
54. A common mutant epidermal growth factor receptor enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis
55. Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and capase-3-like proteases
56. The epidermal growth factor receptor and the prognosis of bladder cancer
57. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity
58. Inhibition of a naturally occurring EGFR oncoprotein by the p185neu ectodomain: Implications for subdomain contributions to receptor assembly
59. Enhanced tumorigenic behavior of glioblastoma cells expressing a truncated epidermal growth factor receptor is mediated through the Ras-Shc-Grb2 pathway
60. Tumor-specific anti-epidermal growth factor receptor variant III monoclonal antibodies: Use of the tyramine-cellobiose radioiodination method enhances cellular retention and uptake in tumor xenografts
61. In vitro and in vivo behavior of radiolabeled chimeric anti-EGFRvIII monoclonal antibody: Comparison with its murine parent
62. Improved targeting of an anti-EGFRvIII monoclonal antibody in tumor xenografts after labeling using N-succinimidyl 5-iodo-3-pyridinecarboxylate
63. Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the 'immunologically privileged' central nervous system
64. An EGFRvIII specific peptide vaccine generates antitumor immunity through a humoral pathway
65. Unarmed, tumor-specific, monoclonal antibody effectively treats brain tumors
66. Amplification of the epidermal-growth factor receptor gene correlates with different growth behaviour in human glioblastoma
67. Expression of an oncogenic mutant EGF receptor markedly increases the sensitivity of cells to an EGF-receptor-specific antibody-toxin
68. Suppression of metastasis formation by a recombinant single chain antibody-toxin targeted to full length and oncogenic variant EGF receptors
69. Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas
70. Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer
71. Localization of aberrant messenger RNA of epidermal growth factor receptor (EGFR) in malignant glioma
72. Epidermal-growth-factor-dependent transformation by a human EGF receptor proto-oncogene
73. Role of an anti-epidermal growth factor receptor in treating cancer
74. Investigation of a synthetic peptide as immunogen for a variant epidermal growth factor receptor associated with gliomas
75. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas
76. Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII
77. The class III variant of the epidermal growth factor receptor [EGFRvIII]: Characterization and utilization as an immunotherapeutic target
78. Antibodies and molecular immunology: Immunohistochemistry and antigens of diagnostic significance
79. Monoclonal antibody therapy of human gliomas: Current status and future approaches
80. Anti-idiotype monoclonal antibody (Mab) vaccine approach to the therapy of variant epidermal growth factor receptor (EGFRvIII)-expressing tumors
81. Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification
82. Structural alterations of the epidermal growth factor receptor gene in human gliomas
83. A deletion mutation within the ligand binding domain is responsible for activation of epidermal growth factor receptor gene in human brain tumors
84. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy